Sarcoidosis
190
24
28
101
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Published Results
15 trials with published results (8%)
Research Maturity
101 completed trials (53% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
6.3%
12 terminated out of 190 trials
89.4%
+2.8% vs benchmark
11%
21 trials in Phase 3/4
15%
15 of 101 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 101 completed trials
Clinical Trials (190)
Janus Kinase Inhibition in Sarcoidosis
Vitamin D Homeostasis in Sarcoidosis
Medication Adherence in Patients With Sarcoidosis
Cardiovascular Multimodality Imaging Study
FAPI PET Imaging - An Exploratory Study
Interstitial Lung Disease Research Unit Biobank
Cardiac Sarcoidosis Randomized Trial
A Study of the Natural Progression of Interstitial Lung Disease (ILD)
EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases
Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions, Cardiovascular Atherosclerosis, Syndrome With Abnormal Immune Activation and sarcoïdosis
Use of CXCL9 as a Biomarker of Acthar Efficacy
Mayo AVC Registry and Biobank
Virtual Patient Groups for Sarcoidosis Associated Fatigue
Evaluation of TNF-alpha Antagonists (Infliximab) Withdrawal in Sarcoidosis
Corticosteroid Tapering in Sarcoidosis
Catheter Ablation Versus Anti-arrhythmic Drugs for Ventricular Tachycardia
Expand Pulmonary Rehabilitation to Other Chronic Respiratory Diseases Than COPD
Immunological Mechanisms in Sarcoidosis
MoMa Signature During Granulomatosis
Rheumatology Patient Registry and Biorepository